v3.22.4
Income Taxes
 12 Months Ended
Jan. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of the net income before the provision for (benefit from) income taxes were as follows:
 Year Ended January 31,
 202320222021
 (in thousands)
Domestic$196,224 $1,047,318 $663,909 
Foreign53,052 54,314 14,125 
Total$249,276 $1,101,632 $678,034 
The provision for (benefit from) income taxes was as follows:
 Year Ended January 31,
 202320222021
 (in thousands)
Current:
Federal$254,505 $69,853 $— 
State33,548 20,174 1,023 
Foreign18,473 12,027 3,933 
Total current income tax expense306,526 102,054 4,956 
Deferred:
Federal(173,941)(293,704)689 
State16,673 (82,561)248 
Foreign(3,693)204 (175)
Total deferred income tax expense(160,961)(376,061)762 
Total provision for (benefit from) income taxes
$145,565 $(274,007)$5,718 
The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal tax rate as follows:
 Year Ended January 31,
 202320222021
 (in thousands, except percentages)
Tax at federal statutory rate$52,277 $231,350 $142,387 
State taxes13,666 24,840 636 
Foreign rate differential1,017 1,830 89 
Non-deductible compensation10,231 — — 
Stock-based compensation124,631 (135,250)(302,362)
Permanent Items9,090 3,971 2,228 
Foreign-derived intangible income deduction(76,686)(34,131)— 
Research and development credits(38,127)(42,973)(3,170)
Tax uncertainties2,296 244 (607)
Change in valuation allowance39,288 (322,231)165,869 
Deferred rate change2,014 — — 
Other5,868 (1,658)648 
Total$145,565 $(274,007)$5,718 
Effective tax rate58.4 %(24.9)%0.8 %
Deferred income taxes result from differences in the recognition of amounts for tax and financial reporting purposes, as well as operating loss and tax credit carryforwards. Significant components of our deferred income tax assets as of January 31, 2023 and 2022 are as follows:
 
As of January 31,
 20232022
 (in thousands)
Deferred tax assets:
Net operating loss carryforwards$14,788 $21,558 
Research and development credit carryforwards12,792 9,985 
Stock-based compensation116,798 44,490 
Accruals and reserves39,758 14,475 
Deferred revenue303,167 260,322 
Capitalized research expenditures245,708 131,010 
Operating lease liabilities23,140 25,892 
Total deferred tax assets756,151 507,732 
Valuation allowance(53,570)(12,605)
Total deferred tax assets net of valuation allowance702,581 495,127 
Deferred tax liabilities:
Property and equipment and intangible assets(36,274)(26,733)
Deferred contract acquisition costs(89,839)(62,814)
Operating right-of-use assets(19,352)(23,466)
Total deferred tax liabilities(145,465)(113,013)
Net deferred tax assets$557,116 $382,114 

The realization of tax benefits of net deferred tax assets is dependent upon future levels of taxable income, of an appropriate character, in the periods the items are expected to be deductible or taxable. Based on the available objective evidence during the year ended January 31, 2023, we continue to believe that it is more likely than not that the tax benefits of the U.K. net deferred tax assets may not be realized. Accordingly, we maintained a full valuation allowance against the tax benefits of these net deferred tax assets. Based on the available objective evidence during the year ended January 31, 2023, we believe that it is more likely than not that the tax benefits relating to U.S. losses that are capital in nature may not be realized prior to expiration. Accordingly, we have maintained a valuation allowance against these deferred tax assets. Based on the available objective evidence during the year ended January 31, 2023, we believe that it is more likely than not that the tax benefits of certain state net deferred tax assets may not be realized. Management applied significant judgement in assessing the positive and negative evidence available in the determination of the amount of certain state deferred tax assets that were more likely than not to be realized in the future. Accordingly, given our current earnings, anticipated future earnings, and continued accumulation of certain state tax credits, we have recorded a full valuation allowance against the tax benefits of these deferred tax assets. We intend to maintain the applicable valuation allowance until sufficient positive evidence exists to support a reversal of, or decrease in, the valuation allowance.
As of January 31, 2023, we had net operating loss carryforwards of approximately $22.9 million for federal income tax purposes, $26.9 million for state income tax purposes, which will begin to expire in the year 2033 if unused. We also had certain foreign net operating loss carryforwards of $32.5 million, which have an indefinite life.
As of January 31, 2023, we also had research and development credit carryforwards of approximately $1.2 million for federal income tax purposes and $22.8 million for state income tax purposes. The federal research and development tax credits have a twenty-year carryover period while the state research and development tax credits carry forward indefinitely.
The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code of 1986 and similar provisions under state law. Such provisions limit the net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. We have completed a Section 382 review and determined that materially none of our operating losses will expire solely due to Section 382 limitation(s).
We indefinitely reinvest earnings from our foreign subsidiaries and therefore no deferred tax liability has been recognized on the basis difference created by such earnings. We have not provided foreign withholding taxes for any undistributed earnings of our foreign subsidiaries.
A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:
Unrecognized Tax Benefits (in thousands)Year Ended January 31,
 202320222021
   
Balance, beginning of year$19,171 $14,884 $8,106 
Tax Positions taken in prior year:
Gross increases877 — 314 
Gross decreases— (3,764)— 
Tax Positions taken in current year:
Gross increases10,547 8,211 6,001 
Gross decreases— — — 
Lapse of Statute of Limitations(191)(160)(422)
Acquisitions— — 885 
Balance, end of year$30,404 $19,171 $14,884 
As of January 31, 2023, gross unrecognized tax benefits related to uncertain tax positions were $30.4 million ($32.5 million total, including $1.6 million associated with interest and penalties). As of January 31, 2022, gross unrecognized tax benefits related to uncertain tax positions were $19.2 million ($19.6 million total, including $0.4 million associated with interest and penalties). As of January 31, 2021, gross unrecognized tax benefits related to uncertain tax positions were $14.9 million ($15.0 million total, including $0.1 million associated with interest and penalties). We recognized approximately $1.6 million, $0.4 million, and $0.1 million in potential interest and penalties associated with uncertain tax positions during fiscal years ended January 31, 2023, 2022, and 2021, respectively. To the extent taxes are not assessed with respect to uncertain tax positions, substantially all amounts accrued (including interest and penalties) will be reduced and reflected as a reduction of the overall income tax provision. Unrecognized tax benefits and associated accrued interest and penalties are included in our income tax provision.
We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and various foreign jurisdictions. As of January 31, 2023, all of the years remain open to examination by the federal and state tax authorities, for three or four years from the tax year in which net operating losses or tax credits are utilized. We believe that an adequate provision has been made for any adjustments that may result from tax examinations. Although the timing of the resolution, settlement, and closure of audits is not certain, we do not believe it is reasonably possible that our unrecognized tax benefits will materially change in the next 12 months.
As required by the 2017 Tax Cuts and Jobs Act, we are capitalizing research and development expenses incurred in fiscal year 2023. These expenses are capitalized and amortized over five years for domestic research and fifteen years for international research. The mandatory capitalization requirement increased our cash tax liabilities but also decreased our effective tax rate due to increasing the foreign-derived intangible income deduction. The cash flow impact may decrease over time as capitalized research and development expenditures continue to amortize.

The Inflation Reduction Act was signed into law in August 2022. The act included tax provisions for a 15% corporate book income minimum tax effective for tax years beginning after December 31, 2022. We do not expect the Inflation Reduction Act to have a material impact on our consolidated financial statements.